Virios Therapeutics Inc. (VIRI) NASDAQ

$4.09 -0.26 (-6.00%)

Market Cap: $36.25M

As of 06/28/22 04:30 PM EDT. Market closed.

(VIRI)

Virios Therapeutics Inc. (VIRI) NASDAQ

$4.09 -0.26 (-6.00%)

Market Cap: $36.25M

As of 06/28/22 04:30 PM EDT. Market closed.

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ('HSV-1') has been postulated to be a potential root cause of chronic illnesses such as ... read more

Virios Therapeutics is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia ('FM'). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 ('HSV-1') has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease ('IBS'), chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease. While not completely understood, there is general agreement in the medical community that activation of HSV-1 is triggered by some form of environmental and/or health stressor. Our lead development candidate ('IMC-1'), is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden. read less

COMPANY PROFILE
Sector
Industry
URL
Address
.
Sector
Industry
Full Time Employees
3
Address
.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$4.12
Previous Close
$4.35
Days Range
$3.88 - $4.25
52 week range
$3.30 - $7.21
Volume
36,147
Avg. Volume (30 days)
14,449
Market Cap
$36.25M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
8,330,390
Open
$4.12
Previous Close
$4.35
Days Range
$3.88 - $4.25
52 week range
$3.30 - $7.21
Volume
36,147
Avg. Volume (30 days)
14,449
Market Cap
$36.25M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
8,330,390

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR VIRIOS THERAPEUTICS INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Walsh Angela SVP OF FINANCE May 23, 2022 Buy $4.57 2,000 9,150 3,000 May 24, 2022, 02:53 PM
Duncan Gregory Scott CHIEF EXECUTIVE OFFICER May 23, 2022 Buy $4.52 7,500 33,900 32,461 May 24, 2022, 10:24 AM
Whitley Richard James Director May 18, 2022 Buy $4.53 500 2,263 2,500 May 19, 2022, 11:48 AM
Pridgen William Director May 18, 2022 Buy $4.50 241 1,085 36,710 May 19, 2022, 11:44 AM
Pridgen William Director May 17, 2022 Buy $4.38 13,450 58,914 36,469 May 18, 2022, 11:24 AM
Pridgen William Director Mar 29, 2022 Buy $4.94 600 2,964 23,019 Mar 30, 2022, 11:55 AM
Pridgen William Director Mar 23, 2022 Buy $5.46 2,197 12,002 22,419 Mar 24, 2022, 02:52 PM
Pridgen William Director Jan 27, 2022 Buy $5.98 4,180 24,998 18,722 Jan 28, 2022, 03:30 PM
De La Rosa Abel Director Jan 07, 2022 Buy $5.90 4,000 23,584 4,000 Jan 07, 2022, 05:24 PM
Whitley Richard James Director Jan 06, 2022 Buy $5.72 1,800 10,296 2,000 Jan 07, 2022, 01:14 PM
Keefer David R Director Jan 04, 2022 Buy $5.80 5,000 28,975 5,000 Jan 05, 2022, 03:12 PM
Pridgen William Director Jan 03, 2022 Buy $5.43 2,215 12,034 14,542 Jan 04, 2022, 03:23 PM
Thomas John C Director Jan 04, 2022 Buy $5.65 1,000 5,650 1,000 Jan 04, 2022, 03:19 PM
Whitley Richard James Director Dec 23, 2021 Buy $5.72 200 1,145 200 Dec 23, 2021, 03:59 PM
Pridgen William Director Dec 21, 2021 Buy $5.66 8,827 49,997 12,327 Dec 22, 2021, 01:28 PM
Duncan Gregory Scott CHIEF EXECUTIVE OFFICER Dec 21, 2021 Buy $5.52 5,000 27,615 24,961 Dec 22, 2021, 01:23 PM
Pridgen William Director Jul 07, 2021 Buy $6.32 942 5,951 710,734 Jul 09, 2021, 01:36 PM
Duncan Gregory Scott Chief Executive Officer Apr 06, 2021 Buy $6.36 382 2,429 19,961 Apr 07, 2021, 01:59 PM
Duncan Gregory Scott Chief Executive Officer Apr 05, 2021 Buy $6.17 15,675 96,757 19,579 Apr 06, 2021, 09:56 PM
Walsh Angela VP of Finance Jan 28, 2021 Buy $7.30 1,000 7,300 1,000 Feb 01, 2021, 07:54 PM
Pridgen William Director Jan 28, 2021 Option Exercise $7.80 801 6,248 727,993 Feb 01, 2021, 07:54 PM
Pridgen William Director Jan 29, 2021 Buy $7.47 3,500 26,145 3,500 Feb 01, 2021, 07:54 PM
Keefer David R Director Jan 28, 2021 Option Exercise $7.80 1,602 12,496 7,808 Feb 01, 2021, 07:54 PM
Duncan Gregory Scott Chief Executive Officer Jan 06, 2021 Option Exercise $7.80 801 6,248 3,904 Jan 08, 2021, 07:23 PM
Pridgen William Director Dec 17, 2020 Buy $11.98 1,500 17,970 727,192 Dec 21, 2020, 08:10 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Walsh Angela SVP OF FINANCE 05/23/2022 9,150
Duncan Gregory Scott CHIEF EXECUTIVE OFFICER 05/23/2022 33,900
Whitley Richard James Director 05/18/2022 2,263
Pridgen William Director 05/18/2022 1,085
Pridgen William Director 05/17/2022 58,914
Pridgen William Director 03/29/2022 2,964
Pridgen William Director 03/23/2022 12,002
Pridgen William Director 01/27/2022 24,998
De La Rosa Abel Director 01/07/2022 23,584
Whitley Richard James Director 01/06/2022 10,296
Keefer David R Director 01/04/2022 28,975
Pridgen William Director 01/03/2022 12,034
Thomas John C Director 01/04/2022 5,650
Whitley Richard James Director 12/23/2021 1,145
Pridgen William Director 12/21/2021 49,997
Duncan Gregory Scott CHIEF EXECUTIVE OFFICER 12/21/2021 27,615
Pridgen William Director 07/07/2021 5,951
Duncan Gregory Scott Chief Executive Officer 04/06/2021 2,429
Duncan Gregory Scott Chief Executive Officer 04/05/2021 96,757
Walsh Angela VP of Finance 01/28/2021 7,300
Pridgen William Director 01/28/2021 6,248
Pridgen William Director 01/29/2021 26,145
Keefer David R Director 01/28/2021 12,496
Duncan Gregory Scott Chief Executive Officer 01/06/2021 6,248
Pridgen William Director 12/17/2020 17,970
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2021
09/30/2021
0%
1Q
12/31/2021
06/30/2021
0.01%
2Q
12/31/2021
03/31/2021
0.04%
3Q

Period of Report: 12/31/2021

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2021
0%
1Q
06/30/2021
0.01%
2Q
03/31/2021
0.04%
3Q